Ameer Khan, MD
Family Medicine · Lake Charles, LANPI 1376743575
Payments from drug & device makers
Across 218 payments — averaging $20.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$928
- AstraZeneca$922
- Amgen$392
- Novo Nordisk$296
- Lilly USA, LLC$239
- Bayer$162
- plus $1K from 31 others
What the payments were for
- Food & beverage$4,34399%
- Education$221%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 59 | $928 |
| AstraZeneca | 44 | $922 |
| Amgen | 11 | $392 |
| Novo Nordisk | 20 | $296 |
| Lilly USA, LLC | 14 | $239 |
| Bayer | 8 | $162 |
| KCI USA, Inc. | 1 | $124 |
| Gilead | 1 | $120 |
| Mimedx Group, Inc. | 2 | $114 |
| Sanofi-aventis U.S. LLC | 7 | $110 |
| GSK | 5 | $91 |
| Pfizer | 4 | $85 |
| Angiodynamics, Inc. | 1 | $74 |
| Sumitomo Pharma America, Inc. | 5 | $56 |
| Exact Sciences | 3 | $52 |
| Boehringer Ingelheim | 3 | $50 |
| Smith+Nephew | 2 | $45 |
| Nestle Healthcare Nutrition Inc. | 2 | $39 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $38 |
| Avanir Pharmaceuticals, Inc. | 2 | $37 |
| Esperion Therapeutics, Inc. | 2 | $36 |
| Vanda Pharmaceuticals Inc. | 2 | $33 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $33 |
| Intuitive Surgical | 1 | $33 |
| Johnson & Johnson | 1 | $29 |
| Novartis | 2 | $28 |
| Idorsia Pharmaceuticals US Inc | 2 | $26 |
| Emmaus Medical, Inc. | 1 | $26 |
| Ardelyx, Inc. | 1 | $20 |
| Lundbeck LLC | 1 | $19 |
| Kowa Pharmaceuticals America, Inc. | 1 | $17 |
| Astellas Pharma US Inc | 1 | $17 |
| Dexcom, Inc. | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Phathom Pharmaceuticals, Inc. | 1 | $14 |
| Abbott | 1 | $14 |
| Organogenesis Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Repatha$125
- Otezla$125
- VAC VERAFLO$124
- Epclusa$120
How this compares
$4,365 in reported general payments places this provider in the 75th percentile of 1,469 family medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 146 | $150,184 |
| EliquisApixaban | 312 | $148,144 |
| TradjentaLinagliptin | 191 | $81,979 |
| TrulicityDulaglutide | 63 | $65,393 |
| JardianceEmpagliflozin | 102 | $63,795 |
| MounjaroTirzepatide | 53 | $55,665 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 69 | $50,419 |
| MyrbetriqMirabegron | 112 | $46,265 |
| LinzessLinaclotide | 68 | $42,984 |
| XifaxanRifaximin | 12 | $38,576 |
| FarxigaDapagliflozin Propanediol | 64 | $37,510 |
| XareltoRivaroxaban | 58 | $31,175 |
| JanuviaSitagliptin Phosphate | 62 | $28,569 |
| Repatha SureclickEvolocumab | 38 | $21,587 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 19 | $20,362 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimTradjenta, Jardiance, Trijardy Xr, Synjardy | $50 | $170,915334 claims |
| Novo NordiskOzempic | $296 | $150,184146 claims |
| PfizerEliquis | $85 | $148,144312 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $239 | $121,058116 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $922 | $53,25688 claims |
| GSKTrelegy Ellipta | $91 | $50,41969 claims |
| Astellas Pharma US IncMyrbetriq | $17 | $46,265112 claims |
| AbbVieLinzess | $928 | $42,98468 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $16 | $38,57612 claims |
| Johnson & JohnsonXarelto | $29 | $31,17558 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $110 | $20,36219 claims |
| BayerKerendia | $162 | $9,12815 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,469 family medicine providers in Louisiana.
Other family medicine in Lake Charles
- Jason MorrisLake Charles$18M
- Michael SeepLake Charles$9.1M
- William NaboursLake Charles$3M
- Joshua WhatleyLake Charles$366K
- Robert VangossenLake Charles$14K
- Clinton GuilloryMonroe$18.5M
- Ramon VargasKenner$2.1M
- Stephen JonesNew Orleans$513K
- Richard JeansonneMandeville$362K
- Kristen ThomasNew Orleans$361K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.